Latest news and press releases about Kyverna Therapeutics, Inc. (KYTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis.
Price
| Price | $6.90 |
| Market Cap | $419M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.39 |
| EV / EBITDA | -2.96 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -81.91% |
| Return on Invested Capital | -80.05% |
| Return on Assets | -69.44% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALLO · AVIR · CABA · CAPR · CTNM · EDIT · LXEO
Explore sector: Healthcare · Biotechnology
More sections of KYTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks